Back to all people

Cong Chen

Merck & Co., Inc.

2 appearances in the program

Sessions & presentations

PS51: Leveraging Duration of Response: Enhancing Efficiency in Treatment Effect Quantification and Predictability for Go/No-Go Decisions in Oncology Trials

Presentation: Projecting Anti-Tumor Activity of new SOC in 1L NSCLC

Parallel · Fri, Sep 26 , 2:50 PM

Presenting Author

PS21: From Dose Selection to Adaptation: Recent Innovations in Oncology Trials

Presentation: Adaptive Phase 2/3 Design with Dose Selection: A Primer

Parallel · Thu, Sep 25 , 4:15 PM

Presenting Author

↑